Alivus Life Sciences Announces 15th AGM on September 8, 2026
Alivus Life Sciences will hold its 15th AGM on September 8, 2026, via video conference. The company reported consolidated revenue of ₹1,817.66 crore and profit after tax of ₹583.26 crore for Q1 FY27. Standalone revenue was ₹5,543.66 crore with PAT of ₹1,215.55 crore.
The AGM announcement is a standard corporate event. The financial results provide key performance indicators for the quarter.
The announcement is a routine disclosure regarding the AGM and financial results, with no significant positive or negative news.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced that its 15th Annual General Meeting (AGM) will be held on Tuesday, September 8, 2026, at 3:00 p.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM). This announcement is in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has published advertisements in Financial Express (English) and Loksatta (Marathi) on August 6, 2026, to inform its members about the AGM, e-voting, and the process for registering email addresses. The financial results for the quarter ended June 30, 2026, are also provided, showing consolidated revenue of ₹1,817.66 crore and a consolidated profit after tax of ₹583.26 crore. Standalone revenue for the same period was ₹5,543.66 crore, with a profit after tax of ₹1,215.55 crore. The company also detailed the process for e-voting and accessing financial information on its website and stock exchange portals.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.